Sanofi Pasteur signs research deal with nanocarrier developer
This article was originally published in Scrip
Executive Summary
Sanofi Pasteurhas signed a research agreement with the privately held French biotechnology company In Cell Art to explore In Cell Art's nanocarrier technologies in Sanofi Pasteur's vaccine programmes. The nanocarriers form novel supramolecular groups that lead to efficient cellular and humoral responses for both prophylactic and therapeutic applications. In Cell Art hopes that if results from studies undertaken in the agreement are positive, the evaluation of its nanocarrier technologies will continue into Sanofi Pasteur's vaccine development. In Cell